Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial (Q45362445)

13 December 2017

Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial (English)

1 reference

13 December 2017

1 reference

10

Pierre Van Damme

1 reference

13 December 2017

7

Michael Wolzt

1 reference

13 December 2017

15

Otfried Kistner

1 reference

13 December 2017

16

Thomas R Kreil

1 reference

13 December 2017

4

Sandor Fritsch

1 reference

13 December 2017

2

Hartmut J Ehrlich

1 reference

13 December 2017

17

P Noel Barrett

1 reference

13 December 2017

Gerald Aichinger

1

1 reference

13 December 2017

John G Aaskov

3

1 reference

13 December 2017

Christiane Thomasser

5

1 reference

13 December 2017

Wolfgang Draxler

6

1 reference

13 December 2017

Markus Müller

8

1 reference

13 December 2017

Fritz Pinl

9

1 reference

13 December 2017

Annick Hens

11

1 reference

13 December 2017

Jack Levy

12

1 reference

13 December 2017

Daniel Portsmouth

13

1 reference

13 December 2017

Georg Holzer

14

1 reference

13 December 2017

language of work or name

English

0 references

publication date

12 October 2011

1 reference

13 December 2017

1 reference

13 December 2017

29

1 reference

13 December 2017

50

1 reference

13 December 2017

9376-9384

1 reference

Ross River virus transmission, infection, and disease: a cross-disciplinary review

13 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Ross River virus and Barmah Forest virus infections: a review of history, ecology, and predictive models, with implications for tropical northern Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Algorithm AS 183: An Efficient and Portable Pseudo-Random Number Generator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Development of a candidate vaccine against Ross River virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Field effectiveness of vaccination against tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

An inactivated cell-culture vaccine against yellow fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Japanese encephalitis: new options for active immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Immunologic interference from sequential administration of live attenuated alphavirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Immune interference after sequential alphavirus vaccine vaccinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Live flavivirus vaccines: reasons for caution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

Safety concerns with regard to live attenuated flavivirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.09.125

10.1016/J.VACCINE.2011.09.125

7 January 2021

Identifiers

DOI

1 reference

13 December 2017

1 reference